

February 5, 2014

Astellas: Reorganization of Astellas' Global Management Structure

TOKYO, February 5, 2014 - Astellas Pharma Inc. ("Astellas" ; President and CEO: Yoshihiko Hatanaka) announced today that it will implement the following revisions to its global management structure effective from April 1, 2014:

【Global Management Structure】

1. Global Development Head will report to Chief Medical Officer ("CMO") from April 1, 2014 (currently reports to CEO).
2. Global Regulatory Affairs Head, Global Clinical and Research Quality Assurance Head, and Global Quality Assurance Head will report to CMO from April 1, 2014 (currently report to QA and RA Head of Astellas Pharma Inc.). Accordingly, the position of QA and RA Head of Astellas Pharma Inc. will be dissolved.

Objective

For the purpose of enhancing global product compliance and the overall synergy with Global Development, Astellas has decided that all Heads of Global Development, GRA^{*}, GCRQA^{*}, and GQA^{*} will report to CMO, while Heads of GPV^{*} and GMA^{*} have already reported to CMO since April 1, 2013.

- * GPV: Global Pharmacovigilance
 - * GMA: Global Medical Affairs
 - * GRA: Global Regulatory Affairs
 - * GCRQA: Global Clinical and Research Quality Assurance
 - * GQA: Global Quality Assurance
-

【Top Management Structure】

Along with revisions to the global management structure, new global report line structure will be changed as below, effective from April 1, 2014.

Title	Divisional Responsibilities
President and CEO (Chief Executive Officer)	Internal Auditing, Medical Affairs, Drug Discovery Research, Technology, Japan Sales & Marketing, Asia/Oceania Business, EMEA Operations, Americas Operations
Executive Vice President, CAO & CCO (Chief Administrative Officer & Chief Compliance Officer)	External Relations, General Affairs, Human Resources, Legal & Compliance, Executive Office
Senior Vice President and CFO (Chief Financial Officer)	Corporate Finance & Control, Accounting & Tax, Corporate Communications, Procurement, Information Systems
Senior Vice President and CSTO (Chief Strategy Officer)	Corporate Planning, Product and Portfolio Strategy, Licensing & Alliances, Innovation Management, Intellectual Property
CMO (Chief Medical Officer)	Global Development, GPV, GMA, GRA, GCRQA, GQA

Global Management Committee

The members of the Global Management Committee will be changed as below, effective from April 1, 2014.

Global Management Committee	
Issues for deliberation: Globally important issues spanning function and geographical regions	
President and CEO	Yoshihiko Hatanaka
Executive Vice President, CAO & CCO	Yoshiro Miyokawa
Senior Vice President and CFO	Yasumasa Masuda
Senior Vice President and CSTO	Kenji Yasukawa
CMO and President, Global Development	Sef Kurstjens
Senior Vice President and President, Drug Discovery Research	Wataru Uchida
Senior Vice President and President, Technology	Mitsunori Matsuda
Senior Vice President and President, Sales & Marketing Japan	Yukihiko Sato
Senior Vice President and President, Asia/Oceania Business	Masatoshi Kuroda
President and CEO EMEA Operations	Ken Jones
President and CEO Americas Operations	Masao Yoshida

###

For inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201, FAX:+81-3-5201-7473 http://www.astellas.com/en